Thyroid dermopathy responds to teprotumumab therapy

Ricaurte Crespo-Trevino, Jade Schiffman, Shoaib Ugradar, Kimberly Cockerham, Raymond Douglas, David de Leon-Garza, Rosa Tang

Research output: Contribution to journalArticlepeer-review


Thyroid dermopathy is an uncommon manifestation of thyroid disease that impairs the quality of life in certain cases. Currently, the available treatments offer limited results and a chance of recurrence. Teprotumumab, a novel medication that results in the regression of thyroid ophthalmopathy, may have similar effects on dermopathy. We describe four patients treated with teprotumumab for their thyroid ophthalmopathy who concomitantly had dermatopathy upon initiation of their infusions. Patients improved after two to three infusions and three out of the four patients have not suffered a recurrence. Teprotumumab is a monoclonal antibody (MAB) that attenuates an inflammatory response, resulting in decreased edema and tissue expansion. Given the similarities of their pathophysiology, we believe that the resolution of thyroid dermatopathy and regression of thyroid eye disease occurs via the same mechanism. We encourage further investigation utilizing teprotumumab for patients whose dermopathy is associated with impaired quality of life.

Original languageEnglish (US)
Article number21-0201
JournalEndocrinology, Diabetes and Metabolism Case Reports
Issue number1
StatePublished - Jan 2022

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Thyroid dermopathy responds to teprotumumab therapy'. Together they form a unique fingerprint.

Cite this